Cardiovascular disease is the leading cause of morbidity and mortality in people with type 2 diabetes (T2DM), adding 15 years to chronological age in those over 40 years.Evidence from recent cardiovascular safety trials in T2DM is changing clinical and pharmacy practice in new ways that go beyond A1C lowering. These trials have been designed to gain a better understanding of the cardiovascular effects antihyperglycemic agents have in both primary prevention (i.e., patients at high risk for cardiovascular disease) and secondary prevention (i.e., patients with established cardiovascular disease).This program will support pharmacists in understanding how the pharmaceutical approaches for patients with diabetes has changed in the April 2018 update to the Diabetes Canada guidelines, and the evolving role of pharmacists in vascular protection.
Estimated 1.5 hour(s) of interactive online continuing health education.
Sean Wharton, MD, PharmD
Jessie Haggai, BSc Pharm, CDE
Rob Roscoe, BSc Pharm, ACPR, CDE, CPT, CDE
On completion of this program, participants will be better able to:
- Appreciate the role of nursing staff in identifying and appropriately guiding patients with type 2 diabetes towards non-pharmacological interventions in residential aged care facilities (RACF)
- Demonstrate a comprehensive understanding of nutritional management approaches, focusing on diabetes-specific nutritional therapy (DSNT)
- Have a better understanding of type 2 diabetes monitoring and management for aged adults in RACFs and will be able to educate family members and caregivers regarding type 2 diabetes
- Counsel patients, family members and caregivers, regarding the safe and proper use of diabetes-specific nutritional therapy, with sensitivity to the psychosocial and cultural needs of the aged care population
- Discuss the implications of DSNT on poor glycaemic control in frail aged adults with diabetes